High rates of durable response are achieved with imatinib after treatment with interferon α plus cytarabine: Results from the International Randomized Study of Interferon and STI571 (IRIS) trial

François Guilhot, Brian Druker, Richard A. Larson, Insa Gathmann, Charlene So, Roger Waltzman, Stephen G. O'Brien

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background: Imatinib is the standard of care for newly diagnosed chronic-phase chronic myeloid leukemia. The largest randomized clinical trial of imatinib was the multinational IRIS trial in which 1106 patients were randomized to receive either imatinib 400 mg/day or a standard regimen of interferon-α plus cytarabine. Design and Methods: Patients were allowed to cross over to the opposite treatment for intolerance, lack of response, disease progression, and, following release of the initial efficacy data, reluctance to remain on therapy with interferon-α plus cytarabine. The safety and efficacy of imatinib in patients who crossed over from interferon-α plus cytarabine to imatinib is reported here. Results: Of 553 patients originally assigned to interferon-α plus cytarabine, 65% crossed over to imatinib, of whom 67% continue to receive treatment. After a median of 54 months of imatinib treatment on study, 93% achieved complete hematologic remission, 86% achieved major cytogenetic remission, and 81% achieved a complete cytogenetic remission as the best observed response. Estimated rates of freedom from progression to accelerated or blast phase and overall survival were 91% and 89%, respectively, at 48 months after starting imatinib. Conclusions: This is the largest analysis to date describing the efficacy of imatinib in patients who have received prior therapies for chronic myeloid leukemia and it demonstrates excellent responses to this treatment.

Original languageEnglish (US)
Pages (from-to)1669-1675
Number of pages7
JournalHaematologica
Volume94
Issue number12
DOIs
StatePublished - Dec 2009

Fingerprint

Cytarabine
Interferons
Therapeutics
Cytogenetics
Imatinib Mesylate
Leukemia, Myeloid, Chronic Phase
Blast Crisis
Standard of Care
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Disease Progression
Randomized Controlled Trials
Safety
Survival

Keywords

  • Cytarabine
  • Durable response
  • Imatinib
  • Interferon-α

ASJC Scopus subject areas

  • Hematology

Cite this

High rates of durable response are achieved with imatinib after treatment with interferon α plus cytarabine : Results from the International Randomized Study of Interferon and STI571 (IRIS) trial. / Guilhot, François; Druker, Brian; Larson, Richard A.; Gathmann, Insa; So, Charlene; Waltzman, Roger; O'Brien, Stephen G.

In: Haematologica, Vol. 94, No. 12, 12.2009, p. 1669-1675.

Research output: Contribution to journalArticle

Guilhot, François ; Druker, Brian ; Larson, Richard A. ; Gathmann, Insa ; So, Charlene ; Waltzman, Roger ; O'Brien, Stephen G. / High rates of durable response are achieved with imatinib after treatment with interferon α plus cytarabine : Results from the International Randomized Study of Interferon and STI571 (IRIS) trial. In: Haematologica. 2009 ; Vol. 94, No. 12. pp. 1669-1675.
@article{b230768fdf184a5e94bd46fbfbaa57a4,
title = "High rates of durable response are achieved with imatinib after treatment with interferon α plus cytarabine: Results from the International Randomized Study of Interferon and STI571 (IRIS) trial",
abstract = "Background: Imatinib is the standard of care for newly diagnosed chronic-phase chronic myeloid leukemia. The largest randomized clinical trial of imatinib was the multinational IRIS trial in which 1106 patients were randomized to receive either imatinib 400 mg/day or a standard regimen of interferon-α plus cytarabine. Design and Methods: Patients were allowed to cross over to the opposite treatment for intolerance, lack of response, disease progression, and, following release of the initial efficacy data, reluctance to remain on therapy with interferon-α plus cytarabine. The safety and efficacy of imatinib in patients who crossed over from interferon-α plus cytarabine to imatinib is reported here. Results: Of 553 patients originally assigned to interferon-α plus cytarabine, 65{\%} crossed over to imatinib, of whom 67{\%} continue to receive treatment. After a median of 54 months of imatinib treatment on study, 93{\%} achieved complete hematologic remission, 86{\%} achieved major cytogenetic remission, and 81{\%} achieved a complete cytogenetic remission as the best observed response. Estimated rates of freedom from progression to accelerated or blast phase and overall survival were 91{\%} and 89{\%}, respectively, at 48 months after starting imatinib. Conclusions: This is the largest analysis to date describing the efficacy of imatinib in patients who have received prior therapies for chronic myeloid leukemia and it demonstrates excellent responses to this treatment.",
keywords = "Cytarabine, Durable response, Imatinib, Interferon-α",
author = "Fran{\cc}ois Guilhot and Brian Druker and Larson, {Richard A.} and Insa Gathmann and Charlene So and Roger Waltzman and O'Brien, {Stephen G.}",
year = "2009",
month = "12",
doi = "10.3324/haematol.2009.010629",
language = "English (US)",
volume = "94",
pages = "1669--1675",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "12",

}

TY - JOUR

T1 - High rates of durable response are achieved with imatinib after treatment with interferon α plus cytarabine

T2 - Results from the International Randomized Study of Interferon and STI571 (IRIS) trial

AU - Guilhot, François

AU - Druker, Brian

AU - Larson, Richard A.

AU - Gathmann, Insa

AU - So, Charlene

AU - Waltzman, Roger

AU - O'Brien, Stephen G.

PY - 2009/12

Y1 - 2009/12

N2 - Background: Imatinib is the standard of care for newly diagnosed chronic-phase chronic myeloid leukemia. The largest randomized clinical trial of imatinib was the multinational IRIS trial in which 1106 patients were randomized to receive either imatinib 400 mg/day or a standard regimen of interferon-α plus cytarabine. Design and Methods: Patients were allowed to cross over to the opposite treatment for intolerance, lack of response, disease progression, and, following release of the initial efficacy data, reluctance to remain on therapy with interferon-α plus cytarabine. The safety and efficacy of imatinib in patients who crossed over from interferon-α plus cytarabine to imatinib is reported here. Results: Of 553 patients originally assigned to interferon-α plus cytarabine, 65% crossed over to imatinib, of whom 67% continue to receive treatment. After a median of 54 months of imatinib treatment on study, 93% achieved complete hematologic remission, 86% achieved major cytogenetic remission, and 81% achieved a complete cytogenetic remission as the best observed response. Estimated rates of freedom from progression to accelerated or blast phase and overall survival were 91% and 89%, respectively, at 48 months after starting imatinib. Conclusions: This is the largest analysis to date describing the efficacy of imatinib in patients who have received prior therapies for chronic myeloid leukemia and it demonstrates excellent responses to this treatment.

AB - Background: Imatinib is the standard of care for newly diagnosed chronic-phase chronic myeloid leukemia. The largest randomized clinical trial of imatinib was the multinational IRIS trial in which 1106 patients were randomized to receive either imatinib 400 mg/day or a standard regimen of interferon-α plus cytarabine. Design and Methods: Patients were allowed to cross over to the opposite treatment for intolerance, lack of response, disease progression, and, following release of the initial efficacy data, reluctance to remain on therapy with interferon-α plus cytarabine. The safety and efficacy of imatinib in patients who crossed over from interferon-α plus cytarabine to imatinib is reported here. Results: Of 553 patients originally assigned to interferon-α plus cytarabine, 65% crossed over to imatinib, of whom 67% continue to receive treatment. After a median of 54 months of imatinib treatment on study, 93% achieved complete hematologic remission, 86% achieved major cytogenetic remission, and 81% achieved a complete cytogenetic remission as the best observed response. Estimated rates of freedom from progression to accelerated or blast phase and overall survival were 91% and 89%, respectively, at 48 months after starting imatinib. Conclusions: This is the largest analysis to date describing the efficacy of imatinib in patients who have received prior therapies for chronic myeloid leukemia and it demonstrates excellent responses to this treatment.

KW - Cytarabine

KW - Durable response

KW - Imatinib

KW - Interferon-α

UR - http://www.scopus.com/inward/record.url?scp=73149122765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73149122765&partnerID=8YFLogxK

U2 - 10.3324/haematol.2009.010629

DO - 10.3324/haematol.2009.010629

M3 - Article

C2 - 19648168

AN - SCOPUS:73149122765

VL - 94

SP - 1669

EP - 1675

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 12

ER -